Investigating 2592 patients enrolled in multicentre myeloma trials we found light chain only (LCO) patients had the worst median survival of 1.9 years compared to 2.3 and 2.5 years in patients with IgA and IgG paraproteins (p<0.0001). However IgA/IgG patients with similar levels of LC excretion as LCO patients had similarly poor survival which is attributable to renal failure. This results in worse survival during induction therapy and at relapse with no difference in progression free survival between LCO and IgG patients. LC excretion was higher for lambda than kappa types but there was no difference in survival between the two LC types when stratified for level of LC excretion. This highlights that care of renal function is vital to improving survival of any patient with LC excretion. LCO patients were younger (p=0.0002), had worse performance status (p=0.0002) and more lytic lesions (p<0.0001) perhaps reflecting late and missed diagnosis in younger and older LCO patients respectively. There was no difference in presentation characteristics, response, or survival from progression of IgA and IgG patients. The worse survival of IgA patients was due to a shorter progression free survival (median 1.2 versus 1.6 years p<0.0001) which is of importance to maintenance therapy.
SUMMARY
Investigating 2592 patients enrolled in multicentre myeloma trials we found light chain only (LCO) patients had the worst median survival of 1.9 years compared to 2.3 and 2.5 years in patients with IgA and IgG paraproteins (p<0.0001). However IgA/IgG patients with similar levels of LC excretion as LCO patients had similarly poor survival which is attributable to renal failure. This results in worse survival during induction therapy and at relapse with no difference in progression free survival between LCO and IgG patients. LC excretion was higher for lambda than kappa types but there was no difference in survival between the two LC types when stratified for level of LC excretion. This highlights that care of renal function is vital to improving survival of any patient with LC excretion. LCO patients were younger (p=0.0002), had worse performance status (p=0.0002) and more lytic lesions (p<0.0001) perhaps reflecting late and missed diagnosis in younger and older LCO patients respectively. There was no difference in presentation characteristics, response, or survival from progression of IgA and IgG patients. The worse survival of IgA patients was due to a shorter progression free survival (median 1.2 versus 1.6 years p<0.0001) which is of importance to maintenance therapy.
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INTRODUCTION
Accounting for 10% of haematological malignancies Multiple Myeloma (MM) results from proliferation of a neoplastic clone of plasma cells in bone marrow 1 . The disease is heterogeneous in severity and its manifestations which variably include skeletal disease (70%), renal impairment (20%), anaemia (40%) and impaired humoral immunity (80%) [1] [2] [3] [4] . This study assesses whether that heterogeneity of disease is linked to the type of monoclonal immunoglobulin proteins (paraproteins) that the malignant plasma cells secrete. 
RESULTS

Patient characteristics
IgA and IgG patients are alike in all presentation characteristics with the exception of corrected calcium, with hypercalcaemia in 45% of IgA patients compared to 28% of IgG patients (Table   2 ). However there was no difference in the rates of bone fractures, bone pain or lytic lesions between these two groups of patients and as discussed later the increased hypercalcaemia in IgA patients may be artefactual. Presentation characteristics of patients with LCO myeloma are unlike that of IgA or IgG patients. 60% of LCO patients are aged <65years versus 48% of IgA/IgG patients (p=0.0002). 66% of IgA/IgG patients have a serum albumin <35 g/l compared to only 28% of LCO patients (p<0.0001) but this may partly reflect lower albumin concentrations in compensation of high total serum protein levels attributable to paraprotein.
Despite being younger LCO patients have a poorer performance status with 61% having restricted activity or worse compared to 51% of IgA patients and 50% of IgG patients (p=0.0002). LCO patients have a higher incidence of renal impairment with elevated serum creatinine (42% having serum creatinine >199 mmol/l compared to 16% of IgA and 13% of IgG patients; p=0.0001). LCO patients also have a higher incidence of elevated serum beta-2 microglobulin (54% having >8 mg/l compared to 34% and 30% of IgA and IgG patients respectively). An increased incidence of multiple lytic bone lesions (p<0.0001) was observed in LC patients versus IgG and IgA but was not apparent in bone pain or fractures (Table 2) .
Overall survival by paraprotein class
IgG patients were found to have the longest overall survival (median=2.5 yrs, 95% CI=2.3-2.7 yrs) followed by IgA patients (median =2.3 yrs, 95% CI=2.1-2.6) (p=0.01). LCO patients have the shortest overall survival (median=1.9 yrs, 95% CI=1.5-2.3 yrs, p<0.0001, Figure 1 ).
Early deaths and failure to reach plateau
LCO myeloma is associated with early deaths with 19% of LCO patients dying within 100 days compared to 11% of patients presenting with IgA and 12% presenting with IgG myeloma; this increase in early deaths is primarily attributable to renal failure (p=0.01, Table 3 ). LCO patients are less likely to achieve plateau than IgA/IgG patients (48% compared to 56%, p=0.008).
Duration of first plateau phase by paraprotein class
There is little difference in duration of plateau between LCO and IgG patients (p=0.08). Median duration of plateau for IgG is 1.6 yrs (95% CI 1.5-1.8 yrs) and 1.5 yrs for LCO myeloma (95% CI
Survival from first disease progression
Survival from progression is worse for LCO patients. Median survival from disease progression for IgA/IgG is 1.3 yrs (95% CI 1.2-1.5 yrs) compared to 0.9 yrs for LCO myeloma (95% CI 0.7-1.1 yrs, p< 0.0004, Figure 3 ).
Effect of free light chain (flc) excretion on survival
28% of IgA and IgG myeloma patients did not have significant urinary flc excretion and within this group only 2% had renal impairment (Table 4) . 11% IgG and 13% IgA patients had high levels of urine flc excretion (>12g/g creatinine) and 48% of these patients had renal impairment; this compares to a 54% rate of renal impairment in LCO patients with >12g/g creatinine flc excretion. There was no difference between IgG, IgA and LCO myeloma in the probability of renal impairment for a given level of flc excretion (Table 4 ). No differences in overall survival between paraprotein classes stratified by level of urinary light chain excretion were detected (Figure 4 ). No differences in survival were identified between the kappa and lambda light chain types for patients with LCO myeloma when stratified by levels of urinary light chain excretion ( Figure 5 ). There is evidence to suggest superior survival in patients with IgA/IgG kappa light chains compared to IgA/IgG lambda patients. This is only apparent in patients with detectable urinary light chain excretion with IgA/IgG kappa patients having a median survival of 2.4 years (95% CI=2.2-2.7) compared to 2.0 years (95% CI=1.7-2.2) in IgA/IgG lambda patients (p=0.007, Figure 6 ). This probably reflects higher levels (>4g/g) of flc excretion in lambda (30% of lambda patients) versus kappa (21% of kappa patients) (p<0.0001). Increasing levels of (Table 1) .
We have found no differences in the presentation characteristics of IgG versus IgA myeloma patients with the exception of a higher incidence of hypercalcaemia in IgA patients (45% versus 28% p=0.0001 Table 2 ). This higher incidence of hypercalcaemia was not associated with any increased incidence of bone pain, lytic lesions or fractures and we are investigating whether it might reflect an interference of IgA paraproteins with the measurement of corrected serum calcium levels. There was no difference between IgG and IgA patients with respect to early deaths (12% and 11%), percentage achieving plateau phase (56% for both) or survival from disease progression (Figure 3) . The difference in overall survival was wholly attributable to a shorter duration of plateau phase for IgA versus IgG patients (1.2 versus 1.6 years, p<0.0001. Figure 2 ). This clinically important difference should be taken account of in considering maintenance therapy and in interpretation of results of trials of maintenance therapy. The biological cause for this difference in duration of plateau phase might reflect susceptibility to translocation of genes into IgG versus IgA switch regions. IgA patients have been shown to have a higher incidence of t(4;14) and associated early disease progression 25 but we do not have cytogenetic data in our study.
Evidence that light chain disease is a variant of myeloma dates from the report of Gutman et al,
1941
, who described a patient with myeloma, hypoproteinaemia and Bence Jones proteinuria 26 .
Light chain myeloma accounts for 10-20% of all cases of myeloma and it is well established that LCO myeloma is associated with a higher incidence of renal impairment and worse survival [1] [2] [3] [4] [13] [14] [15] [16] [17] . Whether this worse survival is attributable solely to light chain nephrotoxicity or also reflects a biologically more aggressive disease is not clear and the importance of LC excretion to survival of IgG and IgA patients also requires clarification.
Compared to IgG and IgA patients LCO myeloma patients are younger with only 40% aged >65 years compared to 52% of IgG and IgA patients (p=0.0002 Table 2 ). This may reflect biological difference, failure to diagnose LCO myeloma in older patients or failure to enter them into trials.
Despite being younger LCO patients have worse performance status (p=0.0002) and a greater incidence of multiple lytic lesions at diagnosis that may reflect biology of the disease or delay in diagnosis because of the lack of a serum paraprotein. This emphasises the need to assess urine for free light chains and that failure to send urine to the laboratory can delay diagnosis of myeloma; assay of serum for free light chains may mitigate this problem. Paraproteins cause high total serum protein levels and a compensatory reduction in albumin concentration and so it is not surprising that twice as many (72%) LCO patients have a normal serum albumin as IgG and IgA patients (34%), a factor that might confound the use of albumin as a prognostic marker.
LCO patients have a 3 fold higher incidence of renal impairment and elevated levels of serum beta-2 microglobulin at presentation compared to IgG/IgA patients (p=0.0001).
Death within a 100 days occurred in 19% of LCO patients compared to 12% of IgG / IgA patients (Table 3) . This difference was mostly due to renal failure attributable to higher incidence (Table 4) . 78% of LCO patients had >4g/g creatinine flc excretion compared to only 24% of IgG / IgA myeloma patients. Importantly, IgG/IgA patients with the same levels of urinary free light chain excretion as LCO myeloma had the same incidence of renal failure and poor survival (Table 4, Figure 4 ). There has been conjecture as to whether light chain type affects survival. In LCO patients there was no difference in survival between kappa and lambda types when stratified by level of LC excretion Progression free survival reflects the intrinsic biology of the disease and is also an indicator of any treatment benefit. We noted no difference in progression free survival between IgG and LCO myeloma. However survival from progression was worse for LCO myeloma. Response to treatment and relapse in LCO myeloma was conventionally assessed by urine light chain measurements. Studies suggest that kidneys metabolise 20-30 grams of free LC daily 27, 28 . Free light chains are not present in urine until their production and thus serum levels are greatly raised. Recent studies suggest urine free light chain measurements are relatively insensitive for assessing residual disease or early relapse in LCO myeloma 29 . The increase in mortality at relapse may therefore reflect a delay in diagnosing relapse as well as the higher incidence of associated renal impairment. In these patients careful monitoring of disease in plateau phase and pre-emptive therapy early in relapse may reduce further renal damage and thus improve survival.
Newly available serum free light chain analysis may prove to be a more sensitive way of monitoring disease response and relapse in LCO myeloma 29, 30 . This large study demonstrates a strong association between level of free light chain excretion, renal impairment and poor survival irrespective of paraprotein type or light chain class (kappa or lambda). Survival is related to preservation of renal function. Supportive measures to minimise further renal damage, including avoidance of aminoglycosides and NSAIDs and maintenance of hydration are important to avoid deaths during induction therapy and at progression 31, 32 . Choice of chemotherapy and recent expansion of therapeutic options to agents including thalidomide, lenalidomide and bortezomib should take into account their interaction with renal impairment and now provide a greater potential for controlling myeloma in these patients 32, 33, 34, 35 .
Potentially, comparable survival between LC secretors and non-secretors might be achieved. 
